Abeona Therapeutics (NASDAQ:ABEO) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Abeona Therapeutics (NASDAQ:ABEO) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.01, MarketWatch Earnings reports.

Shares of ABEO opened at $1.78 on Friday. Abeona Therapeutics has a one year low of $1.35 and a one year high of $8.41. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 2.45. The stock has a 50-day moving average price of $2.81 and a 200 day moving average price of $2.79.

Several research firms recently commented on ABEO. HC Wainwright began coverage on Abeona Therapeutics in a research note on Tuesday, January 21st. They issued a “buy” rating and a $11.00 target price for the company. Royal Bank of Canada dropped their price target on Abeona Therapeutics from $14.00 to $11.00 and set an “outperform” rating for the company in a research note on Wednesday. Zacks Investment Research lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 2nd. ValuEngine upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. Finally, Mizuho restated a “hold” rating and set a $4.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, December 10th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Abeona Therapeutics has a consensus rating of “Hold” and a consensus target price of $6.65.

In related news, Director Stefano Buono purchased 200,000 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were acquired at an average cost of $2.50 per share, for a total transaction of $500,000.00. Following the transaction, the director now owns 270,000 shares of the company’s stock, valued at $675,000. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 33.60% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

See Also: Net Asset Value

Earnings History for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.